Shengwei Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shengwei Hong has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Tan
Department of Dermatology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
1 shared publication Dong Wang
Department of Acupuncture and Rehabilitation, Jiangsu Second Chinese Medicine Hospital, Nanjing 210017, China
1 shared publication- Guo-Liang Dai
Department of Clinical Pharmacology Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing China
1 shared publication Guoliang Dai
Department of Clinical Pharmacology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China
1 shared publicationHeng Chen
The First Clinical College, Nanjing University of Chinese Medicine, Nanjing 210023, P. R. China
1 shared publicationHua-Xi Hang
The First Clinical College, Nanjing University of Chinese Medicine, Nanjing, 210046, China
1 shared publication
Latest Publications
- 22 December 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 324, 117617
Integrative pharmacology reveals the mechanisms of Erzhi pills, A traditional Chinese formulation, stimulating melanogenesis
- 22 December 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 324, 117617
Integrative pharmacology reveals the mechanisms of Erzhi pills, A traditional Chinese formulation, stimulating melanogenesis
- 6 May 2022
- Published by Elsevier in Phytomedicine
- Vol. 102, 154149
ACSL4 promotes colorectal cancer and is a potential therapeutic target of emodin
- 6 May 2022
- Published by Elsevier in Phytomedicine
- Vol. 102, 154149
ACSL4 promotes colorectal cancer and is a potential therapeutic target of emodin
- Open Access
- 3 September 2018
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (54) , 30937-30945
Coptisine suppresses tumor growth and progression by down-regulating MFG-E8 in colorectal cancer
Treating colorectal cancer (CRC) continues to be a clinical challenge. Coptisine, an alkaloid derived from Coptis chinensis Franch. shows toxic effects on CRC cells, but its underlying mechanism remains elusive. MFG-E8 is involved in tumor growth and progression. Herein, we evaluated the effects of coptisine on MFG-E8 in CRC, and explored the mechanism. The expression of MFG-E8 in CRC and adjacent normal colon tissue samples from patients was detected. The effects of coptisine on CRC cells HCT116 in vitro were evaluated by CCK-8, adhesion and transwell assays. A xenograft tumor model was used to assess the effects of coptisine in vivo. The morphology of CRC tissue was observed by HE staining. Cell signaling was tested using western blotting and immunohistochemical assay. The expression of MFG-E8 in human CRC tissue samples significantly increased compared with that of adjacent normal ones. Coptisine significantly reduced the expressions of MFG-E8 in HCT116 cells and tumor-bearing mice. Moreover, coptisine suppressed the growth, adhesion and metastasis of CRC cells. Coptisine also suppressed the expression of MMP-2 and MMP-9 via the PI3K/AKT signaling pathway. Furthermore, it inhibited epithelial–mesenchymal transition in vivo and in vitro. Coptisine inhibited CRC growth and progression by down-regulating MFG-E8, and is a potential candidate for treatment.
- 3 September 2018
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (54) , 30937-30945
Open AccessCoptisine suppresses tumor growth and progression by down-regulating MFG-E8 in colorectal cancer
Treating colorectal cancer (CRC) continues to be a clinical challenge. Coptisine, an alkaloid derived from Coptis chinensis Franch. shows toxic effects on CRC cells, but its underlying mechanism remains elusive. MFG-E8 is involved in tumor growth and progression. Herein, we evaluated the effects of coptisine on MFG-E8 in CRC, and explored the mechanism. The expression of MFG-E8 in CRC and adjacent normal colon tissue samples from patients was detected. The effects of coptisine on CRC cells HCT116 in vitro were evaluated by CCK-8, adhesion and transwell assays. A xenograft tumor model was used to assess the effects of coptisine in vivo. The morphology of CRC tissue was observed by HE staining. Cell signaling was tested using western blotting and immunohistochemical assay. The expression of MFG-E8 in human CRC tissue samples significantly increased compared with that of adjacent normal ones. Coptisine significantly reduced the expressions of MFG-E8 in HCT116 cells and tumor-bearing mice. Moreover, coptisine suppressed the growth, adhesion and metastasis of CRC cells. Coptisine also suppressed the expression of MMP-2 and MMP-9 via the PI3K/AKT signaling pathway. Furthermore, it inhibited epithelial–mesenchymal transition in vivo and in vitro. Coptisine inhibited CRC growth and progression by down-regulating MFG-E8, and is a potential candidate for treatment.